Skip to content

Evaluation of the therapeutic effect of acupuncture combined with Qixing acupuncture on herpes zoster based on the theory of collateral disease

Evaluation of the therapeutic effect of acupuncture combined with Qixing acupuncture on herpes zoster based on the theory of collateral disease

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061357
Enrollment
Unknown
Registered
2022-06-21
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster

Interventions

control group:Western medicine routine combined with Qixing acupuncture
Treatment group:Western medicine routine combined with Qixing acupuncture combined with acupuncture

Sponsors

Xingtai Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for herpes zoster; 2. Age 18 to 80 years old; 3. No antiviral, analgesic and other related drug treatment before treatment; 4. No history of using immunosuppressants or corticosteroids within the past 1 month; 5. No history of peripheral neuropathy; 6. Voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Combined with other skin diseases; (2) Pregnant or lactating women; (3) Allergic constitution or allergic to the drugs used in this study; ? Eye shingles, ear shingles and other atypical types (such as abrupt, generalized, incomplete, etc.) special types of herpes zoster; ? Patients with psychiatric disorders; ? Those with serious primary diseases of cardiovascular, cerebrovascular, hematopoietic and digestive systems; ? Those who received antiviral or analgesic drug treatment in the past 2 weeks. Note: All patients who meet any one of the above items will be excluded.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale;Efficacy evaluation criteria;postherpetic neuralgia incidence;Pain relief time;Time for stopping blister, scab and desquamation;

Countries

China

Contacts

Public ContactGuo Haichao
491644061@qq.com+86 15103190909

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026